Literature DB >> 35902492

Formulation and Evaluation of Eudragit® RL Polymeric Double Layer Films for Prolonged-Release Transdermal Delivery of Tamsulosin Hydrochloride.

Shereen M Assaf1, Aya M Ghanem2, Shayma'a A Alhaj2, Enam A Khalil3, AlSayed Alarabi Sallam4.   

Abstract

Transdermal drug delivery systems (TDDSs) were developed for prolonged tamsulosin (TMS) delivery. Double layer (DL) TDDSs were prepared using Eudragit® RL by conventional film-forming. Ethylene-vinyl acetate was used as the backing layer, triethylcitrate as plasticizer, and Capmul® PG-8-70 NF and Captex 170 EP as penetration enhancers (PEs). An increase in either drug or PE concentration caused a significant increase in drug permeation flux. Modulation of drug permeation across Strat-M® membrane was examined using a single layer (SL) having the same thickness and drug content as the DLs, while the DLs were formulated to have variable drug spatial distribution across each layer (DL 4:6 and DL 6:4). SL/TDDS showed significantly higher daily drug permeation than DL/TDDSs for the first 4 days which could be related to the presence of high TMS concentration located on the upper surface of SL/TDDS as a result of solute migration of TMS during the drying process. However, this increase was followed by a progressive linear decrease after 5 days. Deflection points that were characterized by lower drug flux had been shown by SL/TDDS at more than one-point times. In contrast, DL 4:6 and DL 6:4 TDDSs demonstrated an ability to sustain TMS delivery for up to 2 weeks.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  Eudragit® RL; Prolonged release; Strat-M® membrane; Tamsulosin hydrochloride; Transdermal double layer patches

Mesh:

Substances:

Year:  2022        PMID: 35902492     DOI: 10.1208/s12249-022-02358-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   4.026


  23 in total

Review 1.  Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.

Authors:  Gabriela Franco-Salinas; Jean J M C H de la Rosette; Martin C Michel
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 2.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).

Authors:  P Abrams; M Speakman; M Stott; D Arkell; R Pocock
Journal:  Br J Urol       Date:  1997-10

4.  Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer.

Authors:  Zhioxiong Wang; Yoshiaki Itoh; Yoshifumi Hosaka; Ichiro Kobayashi; Yoshihisa Nakano; Isamu Maeda; Fusako Umeda; Junji Yamakawa; Masaya Kawase; Kiyohito Yag
Journal:  J Biosci Bioeng       Date:  2003       Impact factor: 2.894

Review 5.  Transdermal drug delivery.

Authors:  Mark R Prausnitz; Robert Langer
Journal:  Nat Biotechnol       Date:  2008-11       Impact factor: 54.908

Review 6.  Benign prostatic hyperplasia.

Authors:  Bilal Chughtai; James C Forde; Dominique Dana Marie Thomas; Leanna Laor; Tania Hossack; Henry H Woo; Alexis E Te; Steven A Kaplan
Journal:  Nat Rev Dis Primers       Date:  2016-05-05       Impact factor: 52.329

7.  Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol.

Authors:  Yanli Gao; Jinying Liang; Jianping Liu; Yan Xiao
Journal:  Int J Pharm       Date:  2009-05-20       Impact factor: 5.875

8.  Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy.

Authors:  Shayara Lopes Ciríaco; Ivana Pereira Santos Carvalho; José Alves Terceiro Neto; José de Sousa Lima Neto; Daniel Henrique Bento de Oliveira; Ana Paula Gomes Pereira Cunha; Ykro Talvanis Duarte Cavalcante; Dayane Tomaz Casimiro da Silva; José Alexsandro da Silva; Ana Lys Bezerra Barradas Mineiro; Maria Zenaide de Lima Chagas Moreno Fernandes; André Luis Menezes Carvalho
Journal:  Colloids Surf B Biointerfaces       Date:  2019-10-13       Impact factor: 5.268

Review 9.  Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

Authors:  M Emberton; E B Cornel; P F Bassi; R O Fourcade; J M F Gómez; R Castro
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

Review 10.  Recent advances in transdermal drug delivery systems: a review.

Authors:  Woo Yeup Jeong; Mina Kwon; Hye Eun Choi; Ki Su Kim
Journal:  Biomater Res       Date:  2021-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.